Compare Regeneron Pharmaceuticals Inc (REGN) vs Workday Inc (WDAY) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Workday (WDAY) trades at $186.28, down 4.86% on the day, but maintains a bullish technical signal with strong moving average support. The company reported Q2 2026 EPS of $2.75, beating estimates of $2.61, marking the third consecutive quarterly beat. Revenue growth remains robust, projected to reach $10.2B in 2026, while net income margin improved to 12.32%. Recent news highlights AI adoption gains and a leadership position in cloud HCM suites.

The outlook is positive with analyst consensus favoring a Buy rating and a $204.52 price target, implying potential upside. Key opportunities include AI-driven subscription growth and expanding margins, but risks involve high valuation multiples and competitive pressures in the enterprise software space. Execution on AI initiatives and sustained profitability are critical for continued stock appreciation.